Manufacturer of drug substance
|
|
- Brooke Harrell
- 8 years ago
- Views:
Transcription
1 Original s and Biosimilars (marketing authorizations in the EU) Date: January ) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin Lilly Lilly E. coli Norditropin Somatropin Novo Nordisk Novo Nordisk E. coli Nutropinaq Somatropin Ipsen Genentech E. coli Somatropin Biopartners Somatropin BioPartners LG Life Sciences Saccharomyces cerevisiae Saizen Somatropin Merck Serono Merck Serono Mouse cells C127 Zomacton Somatropin Ferring Ferring E. coli Omnitrope Somatropin Sandoz Sandoz E. coli Genotropin, Somatropin
2 2) Filgrastim s ORIGINAL PRODUCTS: Neupogen Filgrastim Amgen Amgen E. coli Granocyte Lenograstim Chugai Pharma Chugai Pharma CHO cells Lonquex Lipegfilgrastim Teva Merckle Biotec E. coli Neulasta Pegfilgrastim Amgen Amgen E. coli Ristempa Pegfilgrastim Amgen Amgen E. coli The two products of Amgen (grey) are one product with two brand names, they are produced in one and the same manufacturing plant, are identical among each other and substitutable among each other. BIOSIMILARS: INN (Name of Filgrastim Filgrastim Hexal Sandoz E. coli Neupogen, Filgrastim Hexal Zarzio Filgrastim Sandoz Sandoz E. coli Neupogen, Filgrastim Ratiograstim Filgrastim ratiopharm SICOR Biotech E. coli Neupogen, Filgrastim Tevagrastim Filgrastim Teva SICOR Biotech E. coli Neupogen, Filgrastim Nivestim Filgrastim Hospira Hospira E. coli Neupogen, Filgrastim Grastofil Filgrastim Apotex Intas Pharmaceuticals E. coli Neupogen, Filgrastim Accofil Filgrastim Apotex Intas Pharmaceutical E. coli Neupogen, Filgrastim The products of Hexal and Sandoz are one biosimlar with two brand names (red); the products of Ratiopharm and Teva with three brand names (blue) are one biosimilar as this is the case for the products of Intas Pharmaceuticals (orange). Biosimilars with several brand names are produced in one and the same manufacturing plant of the generic producer, are therefore identical among each other and substitutable among each other. Seite 2/7
3 3) Epoetin s ORIGINAL PRODUCTS: Aranesp Darbepoetin alfa Amgen Amgen CHO cells Erypo Epoetin alfa Janssen-Cilag Johnson & CHO cells Johnson Neorecormon Epoetin beta Roche Roche CHO cells Mircera Methoxy-Poly- Roche Roche CHO cells ethylen-glycol- Epoetin beta Biopoin Epoetin theta Teva Merckle Biotec CHO cells Eporatio Epoetin theta Ratiopharm Merckle Biotec CHO cells The products of Teva and ratiopharm (orange) are one product with two brand names, they are produced in one and the same manufacturing plant, are identical among each other and substitutable among each other. BIOSIMILARS: Abseamed Epoetin alfa medice Lek; Rentschler CHO cells Erypo, Epoetin alfa Epoetin alfa Epoetin alfa Hexal Lek; Rentschler CHO cells Erypo, Epoetin alfa Hexal Binocrit Epoetin alfa Sandoz Lek; Rentschler CHO cells Erypo, Epoetin alfa Retacrit Epoetin zeta Hospira Norbitec CHO cells Erypo, Epoetin alfa Silapo Epoetin zeta Stada Norbitec CHO cells Erypo, Epoetin alfa The products of medice, Hexal and Sandoz are one biosimilar with three brand names (red); die products of Hospira and Stada are one biosimilar with two brand names (blue). Biosimilars with several brand names are produced in one and the same manufacturing plant of the generic producer, are therefore identically among each other and substitutable among each other. Seite 3/7
4 4) Follitropin alfa s ORIGINAL PRODUCT: of drug Gonal-f Follitropin alfa Merck Serono Merck Serono CHO cells BIOSIMILARS: Ovaleap Follitropin alfa Teva Merckle Biotec CHO cells Gonal-f, Follitropin alfa Bemfola Follitropin alfa Finox Biotech Polymun Scientific Immunbiologische Forschung CHO cells Gonal-f, Follitropin alfa Seite 4/7
5 5) Monoclonal Antibodies ORIGINAL PRODUCT: Remicade Infliximab Janssen Biologics of drug Janssen Biologics Mouse cells Inflectra Infliximab Hospira Celltrion Mouse cells Remicade, Infliximab Remsima Infliximab Celltrion Celltrion Mouse cells Remicade, Infliximab The products of Hospira and Celltrion (red) are one product with two brand names, they are produced in one and the same manufacturing plant, are identical among each other and substitutable among each other. Seite 5/7
6 6) Insulin glargine s ORIGINAL PRODUCT: of drug Lantus Insulin glargine Sanofi-Aventis Sanofi-Aventis E. coli of drug Abasaglar Insulin glargine Eli Lilly Lilly del Caribe, Eli Lilly and Company E. coli Lantus, Insulin glargin Seite 6/7
7 7) Fusion proteins ORIGINALPRÄPARAT: Enbrel Etanercept Pfizer Boehringer Ingelheim Pharma, Pfizer Ireland Pharmaceuticals CHO cells of drug Benepali Etanercept Samsung Bioepis Biogen Idec CHO cells Enbrel, Etanercept Seite 7/7
An Industry Perspective
AIPPI World IP Congress 2014 Workshop Pharma 2 Biosimilar pharmaceutical products An Industry Perspective September 16, 2014 Masahisa Yamaguchi, PhD Department Manager Intellectual Property Dept. Chugai
More informationNovember 2015. The Impact of Biosimilar Competition
November 2015 The Impact of Competition Introduction This document sets out to describe the effects on price, volume and share following the arrival and presence of biosimilar competition in the European
More informationPRODUCT INN REFERENCE AUTHORIZATION Omnitrope
PRODUCT INN REFERENCE AUTHORIZATION Omnitrope Genotropin 12/04/2006 somatropin Valtropin (W/D) Humatrope 24/04/2006 Abseamed Binocrit Epoetina alfa hexal Retacrit Silapo Biograstim Filgrastim ratiopharm
More informationBUY. Biosimilar play at attractive valuation BIOCON. Target Price: Rs 640. Key drivers(r&d value (Rs/sh) biosimilar pipeline)
Biosimilar play at attractive valuation We highlight Biocon s base business and biosimilar pipeline are underappreciated by the Streetandthe company (ex-syngene^) trades at attractive valuation of17x FY17
More informationWHITE PAPER AN OUTLOOK ON US BIOSIMILAR COMPETITION
WHITE PAPER AN OUTLOOK ON US BIOSIMILAR COMPETITION ANDREW FISCHER BOURGOIN, BETH NUSKEY APRIL 2013 2 AN OUTLOOK ON US BIOSIMILAR COMPETITION WHITE PAPER ANDREW BOURGOIN andrew.bourgoin@ thomsonreuters.com
More informationLessons for the United States: Biosimilar Market Development Worldwide
Lessons for the United States: Biosimilar Market Development Worldwide Sumant Ramachandra, MD, PhD, MBA Senior Vice President, Chief Scientific Officer Hospira $67B+ of 2012 LMV is expected to face biosimilar
More informationBiological. Medicines. A Focus on Biosimilar. Medicines
TM Biological Medicines TM EuropaBio is the voice of the European biotech Industry. It represents the interests of the industry towards the European institutions so that legislation encourages and enables
More information3rd DVFA Life Science Conference 08 June 2010. Biosimilars. BIOCEUTICALS Arzneimittel AG. Epoetin zeta A case study
3rd DVFA Life Science Conference 08 June 2010 Biosimilars BIOCEUTICALS Arzneimittel AG Epoetin zeta A case study Dr. Michael Mack Member of Executive Board BIOCEUTICALS Arzneimittel AG BIOCEUTICALS Arzneimittel
More informationA Comparison of US and EU Biosimilars Regimes
A Comparison of US and EU Biosimilars Regimes summary statement Economic barriers, along with regulatory complexity and uncertainty, are shaping the biosimilars industry into something entirely different
More informationNo consensus concerning
B i osi m i l ars MARKETS An Analysis of the US Biosimilars Development Pipeline and Likely Market Evolution by Ronald A. Rader No consensus concerning biosimilar-related terminology and definitions has
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved
More informationClinical trial research agreement Agreed schedule 4 or 7 clause amendments
Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for
More informationBiologics: Specific Drug Safety Challenges. Violetta B. Kyburz
Biologics: Specific Drug Safety Challenges Violetta B. Kyburz 2012 2013 2014 Biologics: Specific Drug Safety Challenges Topics for discussion Particular issues in the preclinical development of biologics
More informationCommercial Insight Osteoarthritis and Rheumatoid Arthritis
A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and
More informationRx-360 An International Pharmaceutical Supply Chain Consortium
Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)
More informationTed Quiroz Director, Global Clinical Supply Chain Amgen Inc.
Ted Quiroz Director, Global Clinical Supply Chain Amgen Inc. to serve patients Enbrel (etanercept) EPOGEN (Epoetin alfa) Aranesp (Darbepoetin alfa) Sensipar (cinacalcet HCl) Vectibix (panitumumab) We aspire
More informationCHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
More informationBiosimilar By Name and Biosimilar By Nature
Biosimilar By Name and Biosimilar By Nature The use of unique non-proprietary names for biosimilars has broad implications for brand biologics and FDA s established regulation in the area. Why would the
More informationShaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape
Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape After several
More informationGeneric Biological Treatments and the Associated Cost Savings
Robert J. Shapiro With Karan Singh and Megha Mukim February 2008 The Potential American Market for Generic Biological Treatments and the Associated Cost Savings TABLE OF CONTENTS Introduction...1 Biologics
More informationDecision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)
A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors
More informationehealthinsight Series: Online Patient Recruitment Strategies
A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient
More informationLetter to Shareholders
Letter to Shareholders Robert A. Bradway, Chairman and Chief Executive Officer, Amgen Inc. Dear Shareholders, 2014 was an extraordinary year for Amgen financially, scientifically and organizationally.
More informationA World of Biomanufacturing: Shortages or Global Glut?
A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010 Steady growth
More informationDPC AGGIORNATO AL 25/04/2011 PER SPECIALITA'
DPC AGGIORNATO AL 2/04/20 PER SPECIALITA' 03682029 ABILIFY CPR. 0MG. N0AX2 ARIPIPRAZOLO 2 0368203 ABILIFY CPR. MG. N0AX2 ARIPIPRAZOLO 3 0368207 ABILIFY CPR. MG. N0AX2 ARIPIPRAZOLO 4 03682094 ABILIFY CPR.
More informationOutcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct
Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:
More informationAnnual Press Conference 2012. Business Year 2011
Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation
More informationStakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity
Brochure More information from http://www.researchandmarkets.com/reports/1383065/ Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Description: Introduction Disease-modifying
More informationPlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
More informationPATIENT APPLICATION FORM INSTRUCTIONS
INSTRUCTIONS The Safety Net Foundation is a nonprofit patient assistance program that helps qualifying uninsured patients access Amgen medicines at no cost. To apply online, access program information
More informationGrowth Hormone Deficiency
Growth Hormone Deficiency What is growth hormone deficiency? 1,2 Growth hormone deficiency is when your body doesn t make enough growth hormone. Growth hormone is one of many hormones made by the pituitary
More informationChallenges and Opportunities of Monoclonal Antibody Manufacturing in China
BioPharma Antibody Therapeutics News Digest Challenges and Opportunities of Monoclonal Antibody Manufacturing in China Chris Chen Introduction About the Author: Dr. Chris Chen is currently Chief Operating
More informationISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Article. Biosimilars: Company Strategies to Capture Value from the Biologics Market
Pharmaceuticals 2012, 5, 1393-1408; doi:10.3390/ph5121393 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Article Biosimilars: Company Strategies to Capture Value from the
More informationPPRS 2014 analysis of growth in spend of branded medicines. DH Leading the nation s health and care
PPRS 2014 analysis of growth in spend of branded medicines March 2015 Executive Summary IMS Health data shows growth in spend in 2014 (compared to 2013) of 8.2% on branded medicines. This is higher than
More informationBiosimilars: Commercial Perspective
February 4, 2014 Biosimilars: Commercial Perspective FTC Presentation, February 4 th 2014 Aaron (Ronny) Gal, Ph.D. (Senior Analyst) +1-212-756-4208 ronny.gal@bernstein.com Three topics Commercial rationale
More informationKey Findings. Use this report to... The Autoimmune Market Outlook to 2013
Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.
More informationThe Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011
Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts
More information6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality
6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors
More informationPharmaceutical sales in Canada have a 2.5 percent share of the global market, making th
Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries
More informationStakeholder Perspectives: Mild Cognitive Impairment and Dementia
A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?
More informationBiosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies
Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is
More informationPharma working capital performance highly variable
April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the
More informationPharmaceutical industry
8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and
More informationMultiple Sclerosis Treatments: World Market Outlook to 2011
Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating
More informationBiopharmaceutical Raw Materials throughout the Product Lifecycle
February 27 March 2, 2012 Hilton San Diego Bayfront San Diego, CA Monday Tuesday Programming: IBC s 17th International Process & Analytical Assay Validation IBC s 8th International Outsourcing Manufacturing
More informationCommercial Perspectives: Multiple Sclerosis
A Datamonitor Report Commercial Perspectives: Multiple Sclerosis How to Find Opportunities in an Unremitting Market Published: Jun-04 Product Code: Providing you with: In-depth profiles of current market-leading
More informationBiologics and biosimilars. An overview
Biologics and biosimilars An overview Contents An introduction to biotechnology... 3 A brief history of medicine development... 4 What are biologic medicines?... 5 How are biologic medicines developed?...
More informationHISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS
HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS 1. COMPANY DESCRIPTION Biocad is a Russian full cycle biotechnological company. It deals with development, manufacture and promotion of original
More informationEU Clinical Trials Register
EU Clinical Trials Register Sponsor Contact Information Abbott Laboratories Ltd Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4XE UK Telephone number +44 1628 644475 euclinicaltrials@abbott.com
More informationMultiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth
Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine
More informationStakeholder Insight: Insulin Use in Type 2 Diabetes
A Datamonitor Report Stakeholder Insight: Insulin Use in Type 2 Diabetes From Last Resort to Early Intervention Published: May-04 Product Code: DMHC1989 Providing you with: Analysis of Datamonitor s Diabetes
More informationStakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm
A Datamonitor report Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm Published: Sep-06 Product Code: Providing you with: Disease overview including epidemiology, physician
More informationPalliative Coverage Drug Benefit Supplement
Palliative Coverage Drug Benefit Supplement Effective April 1, 2015 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationPATIENT ASSISTANCE PROGRAMS
PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed
More informationMetastatic Breast Cancer - Pipeline Review, Q1 2011
Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary
More informationPHARMACEUTICAL INDUSTRY PROFILE
PHARMACEUTICAL INDUSTRY PROFILE I. INDUSTRY BACKGROUND A. Industry Definition The U.S. pharmaceutical industry is defined by the Census Bureau as companies engaged in researching, developing, manufacturing,
More informationGlobal Monoclonal Antibodies Pipeline Insight 2015
Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who
More informatione-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015
e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 PHARMAPACK 2015 1 Mobile health x2 30 months 100 000 mapps Source: research2guidance, mhealth App Market Report 2013-2017
More informationWORLD PREVIEW 2014, OUTLOOK TO 2020
WORLD PREVIEW 2014, OUTLOOK TO 2020 June 2014 Welcome to the EvaluatePharma World Preview 2014, Outlook to 2020 The seventh edition of EvaluatePharma s World Preview brings together many of our analyses
More informationCompany Presentation June 2011 Biotest AG 0
Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and
More informationGlobal Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics
More informationCommercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
Brochure More information from http://www.researchandmarkets.com/reports/1504775/ Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
More informationBriefing Paper on Biological and Biosimilar Medicines
Briefing Paper on Biological and Biosimilar Medicines Contents With our thanks IAPO would like to thank all those involved in planning this Toolkit and supporting its development. A full list of acknowledgements
More informationUses of 2D gel electrophoresis in recombinant protein production. Kendrick Laboratories, Inc www.kendricklabs.com
Uses of 2D gel electrophoresis in recombinant protein production Kendrick Laboratories, Inc www.kendricklabs.com Recombinant proteins are biologics What is a Biologic? Biological products are those derived
More informationPatient Assistance PROGRAM PRIMER
Patient Assistance PROGRAM PRIMER The private benefits plan sponsor s guide to the patient assistance program Your guide to pharmaceutical manufacturers patient assistance programs for eligible plan members
More informationTotal Compensation Measurement. Global TCM Participants. Turkey
Total Compensation Measurement 2008 Global TCM Participants Turkey Turkey 2008 TCM Participants Summary Information The table below lists key summary information on the 67 TCM participants for 2008. Measure
More informationImmune-response and adverse reactions: PRCA case example. Nicole Casadevall
Immune-response and adverse reactions: PRCA case example Nicole Casadevall Recombinant human erythropoietin (rhuepo) 1985: EPO gene cloned 1986: first clinical trials in CKD 1988: rhepo is licensed for
More informationMeet Novartis Management
Meet Novartis Management Joseph Jimenez, CEO and Harry Kirsch, CFO June 7-8, 0 Disclaimer This presentation contains forward-looking statements that can be identified by words such as momentum, progress,
More informationBrochure More information from http://www.researchandmarkets.com/reports/3292678/
Brochure More information from http://www.researchandmarkets.com/reports/3292678/ Asia Pacific (India, China, Australia, South Korea & Others) Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long
More informationStakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice
A Datamonitor report Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice Published: Dec-06 Product Code: Providing you with: An overview of epidemiology,
More informationMid-Year Report 2015
1 +2 Mid-Year Report 2015 1 +2 Half Year Report 2015 2 Table of Contents 3 Prefacing Remarks...4 Interim Financial Statements Consolidated Interim Financial Statements Management Report...8 Management
More informationKEEPING CLINICAL TRIALS IN AUSTRALIA
OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought
More informationAnti-CD20 Monoclonal Antibodies - Global Strategic Business Report
Brochure More information from http://www.researchandmarkets.com/reports/1382330/ Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report Description: This report analyzes the Global market
More information(SAMPLE COPY, NOT FOR RESALE)
TriMark Publications June 2009 Volume: TMRTMA09-0601 THERAPEUTIC MONOCLONAL ANTIBODIES MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF
More informationBig Pharma s 2009-2013 Patent Cliff
HONORS CAPSTONE IN BUSINESS Big Pharma s 2009-2013 Patent Cliff A Comparison of Company-Level Responses and Strategic Recommendations for Pfizer, Inc. and Eli Lilly and Company Benjamin Jardines, University
More informationPharma working capital leaves room for improvement
October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.
More informationPatient Satisfaction and Therapeutic Adherence Considerations of rhgh Dosing Devices
Patient Satisfaction and Therapeutic Adherence Considerations of rhgh Dosing Devices Robert Lipsy, PharmD Clinical Assistant Professor Department of Pharmacy Practice and Sciences University of Arizona
More informationIn the largest and perhaps the most ambitious collaborative
FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated
More informationREFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,
More informationThe power of creativity www.originbranding.com. Pharmaceutical Branding 2012
The power of creativity www.originbranding.com Pharmaceutical Branding 2012 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered
More informationPaul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS
Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions
More information全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report
/wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天
More informationPharmaceutical Marketing Disclosures
Pharmaceutical Marketing Disclosures July 1, 2007 June 30, 2008 Report of Vermont Attorney General William H. Sorrell April 2009 Prepared by staff of the Vermont Attorney General s Office: Wendy Morgan,
More informationPipeline Insight: Schizophrenia Asenapine; A future market leader?
A Datamonitor report Pipeline Insight: Schizophrenia Asenapine; A future market leader? Published: Jul-06 Product Code: DMHC2186 Providing you with: Detailed pipeline analysis for key products in development
More informationM&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends
M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends Symposium Life Science am Kapitalmarkt Frankfurt, 3. Juni 28 Global biotech industry Strong growth in most areas but Visible product
More informationOFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013
Introduction OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013 In 2007, Attorney General Wasden filed lawsuits against 33 pharmaceutical companies for
More informationSource: BIO, Factset, NASDAQ
Inside The NBI A guide to performance drivers of the NASDAQ Biotech Index Introduction The NASDAQ Biotechnology Index (NBI) is referenced by investors, CEOs, and industry leaders around the world to take
More informationTriskel: a strategic consulting firm for biopharmaceutical companies
BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland
More informationMRC Technology Centre for Therapeutics Discovery
MRC Technology Centre for Therapeutics Discovery fast-tracking discovery and development of novel drugs from academia Dr Duncan Young Business Development Manager UbiFrance Symposium, October 2012 established
More informationCurrent Regulatory thinking Around Biosimilars A Regulator s Perspective
Current Regulatory thinking Around Biosimilars A Regulator s Perspective Biologics and Biosimilars Symposium; 07 May, 2012 Dr. Elena Wolff-Holz Paul Ehrlich Institut Federal Agency for Vaccines and Biomedicines
More informationAccelerating Drug & Clinical Trial Approvals in China & East Asia
25 28 March 2014 The Westin Beijing Chaoyang, Accelerating Drug & Clinical Trial Approvals in & East Asia What s New in 2014? Key Regulatory Update from the National Institute for Food & Drug Control,
More informationElisabeth B. Reynolds INDUSTRIAL PERFORMANCE CENTER MASSACHUSETTS INSTITUTE OF TECHNOLOGY WORKING PAPER SERIES MIT-IPC-11-001.
INDUSTRIAL PERFORMANCE CENTER MASSACHUSETTS INSTITUTE OF TECHNOLOGY WORKING PAPER SERIES Elisabeth B. Reynolds MIT-IPC-11-001 March 2011 292 Main Street, E38-104, Cambridge, MA 02139-4307 617-253-7522
More informationAhighlight of the Pharma 50 ranking
www.pharmexec.com ELECTRONICALLY REPRINTED FROM JUNE 2014 Insight: The Accelerating Growth of Specialty Markets By Waseem Noor and Michael Kleinrock, IMS Photo: Thinkstock Ahighlight of the ranking over
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationGeneral toxicity study designs
General toxicity study designs Jan Willem van der Laan Section on Safety of Medicines and Teratology Centre for Biological Medicines and Medical Technology National Institute for Public Health and the
More informationDecember 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES
December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage
More informationBuilding innovative drug discovery alliances. Profitable. Growth Go
Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains
More informationProduct Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants
Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with
More informationBIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM
BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM FROM ORIGINATOR THROUGH COMPARABILITY TO MARKET STREAMLINE YOUR R&D, REGULATORY, ANALYTICAL, AND CLINICAL NEEDS WITH ONE PROVIDER The development pathway of
More informationIntroduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs
Introduction to Drug Naming Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs What s in a Name? International Nonproprietary Names (INN) Sponsored by World Health
More information